Compare Stocks: AKTX, ACRV, TELO, and SERA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$1.70	$1.89	$1.27 ▼ $3.56	$72.85M	1.92	261,314 shs	463,728 shs
AKTX Akari Therapeutics	$9.88 -2.4%	$9.43	$3.02 ▼ $49.60	$19.70M	1.43	84,772 shs	126,390 shs
SERA Sera Prognostics	$2.07 +2.5%	$2.05	$1.56 ▼ $3.95	$79.69M	0.98	23,442 shs	7,205 shs
TELO Telomir Pharmaceuticals	$1.12 -0.9%	$1.15	$0.89 ▼ $2.09	$77.72M	-0.25	44,854 shs	146,235 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	-7.10%	-14.57%	-17.07%	+8.28%	+9.68%
AKTX Akari Therapeutics	-1.27%	-4.26%	+34.57%	-7.50%	-66.49%
SERA Sera Prognostics	+1.51%	+1.00%	+3.59%	+15.43%	-34.42%
TELO Telomir Pharmaceuticals	-3.42%	-7.38%	+6.60%	-20.42%	-13.08%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$1.70	$1.89	$1.27 ▼ $3.56	$72.85M	1.92	261,314 shs	463,728 shs
AKTX Akari Therapeutics	$9.88 -2.4%	$9.43	$3.02 ▼ $49.60	$19.70M	1.43	84,772 shs	126,390 shs
SERA Sera Prognostics	$2.07 +2.5%	$2.05	$1.56 ▼ $3.95	$79.69M	0.98	23,442 shs	7,205 shs
TELO Telomir Pharmaceuticals	$1.12 -0.9%	$1.15	$0.89 ▼ $2.09	$77.72M	-0.25	44,854 shs	146,235 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	-7.10%	-14.57%	-17.07%	+8.28%	+9.68%
AKTX Akari Therapeutics	-1.27%	-4.26%	+34.57%	-7.50%	-66.49%
SERA Sera Prognostics	+1.51%	+1.00%	+3.59%	+15.43%	-34.42%
TELO Telomir Pharmaceuticals	-3.42%	-7.38%	+6.60%	-20.42%	-13.08%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRV Acrivon Therapeutics	2.50	Moderate Buy	$13.50	694.12% Upside
AKTX Akari Therapeutics	2.50	Moderate Buy	$32.33	227.26% Upside
SERA Sera Prognostics	2.67	Moderate Buy	$5.50	165.70% Upside
TELO Telomir Pharmaceuticals	2.25	Hold	$4.00	257.14% Upside

Current Analyst Ratings Breakdown

Latest AKTX, ACRV, TELO, and SERA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2026	TELO Telomir Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$4.00
9/10/2026	SERA Sera Prognostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/2/2026	ACRV Acrivon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	ACRV Acrivon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/31/2026	SERA Sera Prognostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/20/2026	AKTX Akari Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$30.00
7/17/2026	TELO Telomir Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/16/2026	SERA Sera Prognostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/15/2026	ACRV Acrivon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/6/2026	AKTX Akari Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/29/2026	ACRV Acrivon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	$3.57 per share	N/A
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	$24.75 per share	N/A
SERA Sera Prognostics	$80K	1,020.77	N/A	N/A	$1.94 per share	1.07
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	$0.17 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRV Acrivon Therapeutics	-$77.90M	-$1.88	N/A	N/A	N/A	N/A	-70.14%	-61.60%	11/12/2026 (Estimated)
AKTX Akari Therapeutics	-$17.30M	N/A	N/A	N/A	N/A	N/A	-147.45%	-74.70%	12/4/2026 (Estimated)
SERA Sera Prognostics	-$31.93M	-$0.67	N/A	N/A	N/A	-47,475.72%	-46.71%	-34.06%	11/12/2026 (Estimated)
TELO Telomir Pharmaceuticals	-$10.41M	-$0.91	N/A	N/A	N/A	N/A	-102.70%	-90.75%	12/2/2026 (Estimated)

Latest AKTX, ACRV, TELO, and SERA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	TELO Telomir Pharmaceuticals	-$0.07	-$0.79	-$0.72	-$0.79	N/A	N/A
8/12/2026	Q2 2026	ACRV Acrivon Therapeutics	-$0.5022	-$0.43	+$0.0722	-$0.43	$0.39 million	N/A
8/12/2026	Q2 2026	SERA Sera Prognostics	-$0.1542	-$0.18	-$0.0258	-$0.18	$0.07 million	$0.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	N/A
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	N/A
SERA Sera Prognostics	N/A	N/A	N/A	N/A	N/A
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRV Acrivon Therapeutics	N/A	7.99	7.99
AKTX Akari Therapeutics	N/A	0.60	0.60
SERA Sera Prognostics	N/A	1.98	1.98
TELO Telomir Pharmaceuticals	N/A	16.16	16.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRV Acrivon Therapeutics	71.62%
AKTX Akari Therapeutics	5.06%
SERA Sera Prognostics	54.64%
TELO Telomir Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ACRV Acrivon Therapeutics	10.50%
AKTX Akari Therapeutics	32.20%
SERA Sera Prognostics	11.30%
TELO Telomir Pharmaceuticals	16.36%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRV Acrivon Therapeutics	76	42.85 million	38.35 million	Not Optionable
AKTX Akari Therapeutics	9	1.95 million	1.32 million	Not Optionable
SERA Sera Prognostics	72	39.45 million	34.99 million	Optionable
TELO Telomir Pharmaceuticals	5	68.78 million	57.52 million	N/A

AKTX, ACRV, TELO, and SERA Headlines

Recent News About These Companies

Telomir Publishes Data Validating Telomir-Zn For AMD Alongside Cancer Indications; Stock Up

2 hours ago | rttnews.com

Telomir-Zn Preclinical Data Highlight Retinal Regeneration Potential

September 17 at 9:11 AM | tipranks.com

Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)

September 17 at 8:30 AM | globenewswire.com

Telomir Pharmaceuticals (NASDAQ:TELO) Trading Down 3.4% - Time to Sell?

September 17 at 1:41 AM | americanbankingnews.com

Telomir unveils new preclinical data for Telomir-Zn

September 14 at 8:51 AM | tipranks.com

Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models

September 14 at 8:00 AM | globenewswire.com

Telomir Pharmaceuticals (TELO) to Post Quarterly Earnings on Wednesday

August 26, 2026 | marketbeat.com

Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Down 3.4% – Should You Sell?

August 12, 2026 | defenseworld.netD

Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models

August 10, 2026 | markets.businessinsider.com

Telomir-Zn Preclinical Data Support Advancement in TNBC

August 10, 2026 | tipranks.com

Telomir Pharmaceuticals Announces Peer-Reviewed Publication of Preclinical Telomir-Zn Data Showing Tumor Suppression in Prostate and Triple-Negative Breast Cancer Models

August 10, 2026 | quiverquant.comQ

TELO Telomir Pharmaceuticals, Inc.

July 8, 2026 | seekingalpha.com

Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical ...

June 15, 2026 | usatoday.com

Telomir Showcases Preclinical Telomir-Zn Diabetes Efficacy Data

June 15, 2026 | tipranks.com

Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model

June 15, 2026 | accessnewswire.comA

Telomir Pharmaceuticals Appoints Fractional CFO After Leadership Change

June 8, 2026 | tipranks.com $https://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-appoints-fractional-cfo-after-leadership-change?utm_source=marketbeat.com&utm_medium=referral$

Telomir Pharmaceuticals Inc TELO

May 26, 2026 | morningstar.comM

Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson’s Disease

May 20, 2026 | usatoday.com

Telomir-Zn Preclinical Data Published in Wilson’s Disease

May 20, 2026 | tipranks.com

Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease

May 20, 2026 | accessnewswire.comA

Telomir Pharmaceuticals Receives FDA IND Clearance for Telomir-Zn

April 30, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKTX, ACRV, TELO, and SERA Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

$1.70 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.76 +0.06 (+3.82%)

As of 07:30 PM Eastern

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Akari Therapeutics NASDAQ:AKTX

$9.88 -0.24 (-2.37%)

Closing price 04:00 PM Eastern

Extended Trading

$9.91 +0.03 (+0.35%)

As of 07:43 PM Eastern

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

Sera Prognostics NASDAQ:SERA

$2.07 +0.05 (+2.48%)

Closing price 04:00 PM Eastern

Extended Trading

$2.07 0.00 (0.00%)

As of 04:10 PM Eastern

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Telomir Pharmaceuticals NASDAQ:TELO

$1.12 -0.01 (-0.88%)

Closing price 04:00 PM Eastern

Extended Trading

$1.17 +0.05 (+4.20%)

As of 07:42 PM Eastern

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AKTX, ACRV, TELO, and SERA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AKTX, ACRV, TELO, and SERA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AKTX, ACRV, TELO, and SERA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKTX, ACRV, TELO, and SERA Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

Akari Therapeutics NASDAQ:AKTX

Sera Prognostics NASDAQ:SERA

Telomir Pharmaceuticals NASDAQ:TELO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AKTX, ACRV, TELO, and SERA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AKTX, ACRV, TELO, and SERA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AKTX, ACRV, TELO, and SERA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKTX, ACRV, TELO, and SERA Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

Akari Therapeutics NASDAQ:AKTX

Sera Prognostics NASDAQ:SERA

Telomir Pharmaceuticals NASDAQ:TELO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools